Recombinant Sheep Neuropeptide Y receptor type 2 (NPY2R)

What is Recombinant Sheep Neuropeptide Y receptor type 2 (NPY2R)?

Recombinant Sheep NPY2R is a laboratory-produced version of the natural Neuropeptide Y receptor type 2 protein found in sheep. It belongs to the class of G-protein coupled receptors that are activated by closely related peptide hormones including neuropeptide Y, peptide YY, and pancreatic polypeptide. The recombinant protein typically consists of the full-length sequence (1-146 amino acids) and can be expressed with various tags (commonly His-tag) to facilitate purification and experimental applications . NPY receptors, including NPY2R, are involved in regulating several critical behavioral and physiological processes including appetite control, circadian rhythm maintenance, and anxiety modulation .

What expression systems are commonly used for Recombinant Sheep NPY2R production?

Escherichia coli (E. coli) is the most commonly documented expression system for recombinant Sheep NPY2R production . This prokaryotic expression system offers advantages including:

For functional studies requiring proper folding and post-translational modifications, researchers sometimes opt for eukaryotic expression systems like yeast, insect cells, or mammalian cells, though these alternatives typically result in lower yields but potentially higher biological activity.

How should Recombinant Sheep NPY2R be reconstituted for optimal activity?

For optimal reconstitution of lyophilized Recombinant Sheep NPY2R:

• Centrifuge the vial briefly before opening to bring contents to the bottom

• Reconstitute the protein in deionized sterile water to achieve a concentration of 0.1-1.0 mg/mL

• For long-term storage, add glycerol to a final concentration of 5-50% (commonly 50%)

• Aliquot the reconstituted protein to avoid repeated freeze-thaw cycles

• Store working aliquots at 4°C for up to one week, and long-term storage at -20°C/-80°C

This protocol helps maintain protein integrity and activity by minimizing denaturation that can occur during repeated freeze-thaw cycles.

What methodologies are most effective for studying NPY2R binding characteristics?

Autoradiographic binding methodology represents one of the most effective approaches for studying NPY2R binding characteristics. This technique typically employs:

• Monoiodinated peptide YY (125I-PYY) as the primary ligand

• Competition with NPY (1-36) and NPY (13-36) to assess binding specificity

• Quantitative measurement of binding in various tissue regions

In experimental settings, approximately 95% of specific binding sites can be displaced by the full-length peptide NPY (1-36) at 10−6M concentration, while approximately 90% can be displaced by the Y2 receptor-specific ligand NPY (13-36) at the same concentration . This displacement pattern confirms Y2 receptor subtype specificity.

For studying NPY2R expression at the mRNA level, in situ hybridization using oligonucleotide probes complementary to Y2-R mRNA provides valuable information about receptor distribution and regulation .

How does NPY2R expression and binding change under pathological conditions?

Studies in mouse models of prion disease have demonstrated significant alterations in NPY2R binding under pathological conditions. These changes include:

These findings indicate that pathological accumulation of prion proteins can dramatically decrease NPY binding capacity at Y2-Rs, particularly in hippocampal regions, while only marginally affecting Y2-R mRNA expression . This suggests that post-transcriptional mechanisms likely play a significant role in the pathological regulation of NPY2R function.

What is the significance of NPY2R in neurological function and disease models?

NPY2R plays a crucial role in modulating neurological functions, particularly in the hippocampus. Research indicates that:

• NPY2Rs are predominantly expressed in pyramidal cell layers of CA1-3 regions and granule cell layer of the dentate gyrus

• These receptors function presynaptically to inhibit glutamate release at the Schaffer collateral-CA1 synapses

• Under pathological conditions (e.g., prion disease), decreased Y2-R binding in the CA1 stratum radiatum may attenuate NPY-mediated inhibition

The dysregulation of NPY2R has been implicated in various neurological conditions:

• In mouse scrapie (prion disease), CA3 pyramidal neurons show increased NPY mRNA expression while Y2-R binding decreases

• Similar changes in NPY system plasticity occur in various forms of hippocampal pathology, including seizure activity and epilepsy

• These alterations may represent compensatory mechanisms to protect neurons against glutamate-induced excitotoxicity

Understanding these mechanisms provides valuable insights for developing therapeutic strategies targeting NPY2R in neurological disorders.

What techniques are recommended for studying NPY2R signaling pathways?

For comprehensive investigation of NPY2R signaling pathways, researchers should consider a multi-modal approach:

• Receptor Binding Assays:

  • Autoradiography with 125I-PYY to quantify binding site density

  • Competition binding with NPY (1-36) and NPY (13-36) to confirm Y2 receptor specificity

• Gene Expression Analysis:

  • In situ hybridization to localize Y2-R mRNA in specific cell populations

  • qRT-PCR for quantitative assessment of mRNA levels

• Functional Studies:

  • Electrophysiological recordings to assess effects on neurotransmitter release

  • Calcium imaging to monitor intracellular signaling

  • cAMP assays to measure G-protein coupled receptor activity

• Protein-Protein Interaction Studies:

  • Co-immunoprecipitation to identify binding partners

  • Proximity ligation assays to verify interactions in situ

These methodologies, when used in combination, provide a comprehensive understanding of NPY2R signaling in both physiological and pathological contexts.

How can researchers validate the specificity of antibodies against Sheep NPY2R?

Validating antibody specificity for Sheep NPY2R requires a systematic approach:

• Western Blot Analysis:

  • Use purified recombinant Sheep NPY2R protein as a positive control

  • Include negative controls (irrelevant protein, blocking peptide competition)

  • Confirm the expected molecular weight (~146 amino acids plus tag size)

• Immunocytochemistry/Immunohistochemistry:

  • Compare staining patterns with published NPY2R distribution data

  • Perform blocking peptide competition to confirm specificity

  • Include negative controls (primary antibody omission, irrelevant primary antibody)

• Cross-Reactivity Testing:

  • Assess reactivity against human and rat NPY2R due to potential species cross-reactivity

  • Note that antibody reactivity and working conditions may vary between species

• Functional Validation:

  • Confirm that the antibody blocks or modulates known NPY2R-mediated responses

  • Test the antibody's ability to immunoprecipitate functional NPY2R

What are common challenges in working with Recombinant Sheep NPY2R and how can they be addressed?

How might Recombinant Sheep NPY2R contribute to neurodegenerative disease research?

The observed changes in NPY2R binding in prion disease models suggest several promising research directions:

• Biomarker Development: The dramatic decrease in Y2-R binding in specific hippocampal regions during prion disease progression suggests potential for developing imaging or biochemical biomarkers for early detection of neurodegenerative processes.

• Neuroprotective Strategies: Understanding the upregulation of NPY in CA3 pyramidal cells and its potential neuroprotective role against glutamate excitotoxicity could inform development of NPY2R-targeted therapies.

• Circuit-Specific Interventions: The region-specific changes in NPY2R binding (e.g., 85% reduction in CA1 vs. 50-65% in CA3) highlight the importance of circuit-specific approaches to therapeutic intervention.

• Synaptic Dysfunction Mechanisms: Investigating how decreased Y2-R binding affects glutamatergic transmission at Schaffer collateral-CA1 synapses may reveal fundamental mechanisms of synaptic dysfunction in neurodegenerative diseases.

• Comparative Neurobiology: Studying Sheep NPY2R alongside human NPY2R could provide insights into conserved pathways relevant to human diseases while leveraging advantages of ruminant models.